At week 24 , virological suppression was achieved in 39 patients ( 76 % , 95 % CI 65-88 ) in the raltegravir 400 mg group , 40 patients ( 78 % , 67-90 ) in the raltegravir 800 mg group , and 32 patients ( 63 % , 49-76 ) in the efavirenz group .